UCLB

Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company has developed the Delta Zero platform, which leverages deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By merging continuous improvement techniques with AI, Carbon Re's cloud-based platform aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions, electricity consumption, and fuel costs in manufacturing. This innovative approach positions Carbon Re as a key player in the effort to drive substantial reductions in carbon emissions across foundational industries.

Astroscreen Ltd is a London-based company that specializes in developing a software as a service (SaaS) platform aimed at detecting astroturfing campaigns, which involve deceptive social media manipulation. Founded in 2018, the platform employs advanced machine learning techniques and human intelligence to identify fake accounts, botnets, and spam across social networks. By leveraging social media bot data, Astroscreen provides disinformation analysts with the tools needed to verify social media influence engagement and cleanse data streams. This enables organizations to combat marketing fraud, safeguard their brands, and obtain reliable insights into social media analytics.

Hazy Limited is a London-based company specializing in automatic data anonymization using artificial intelligence. Founded in 2017, Hazy has developed a platform that allows businesses to share and utilize data securely while ensuring compliance with privacy regulations. The platform intelligently anonymizes personally identifiable information, enabling organizations to access and share valuable datasets without compromising individual privacy. By facilitating the safe movement and use of data, Hazy aims to empower businesses to make informed decisions, innovate technologies, and enhance customer value. The company's approach ensures that data can be shared freely, utilized effectively, and trusted by users, addressing the growing demand for privacy and regulatory compliance in data handling.

Correvate was formed to commercialise a technology that enables the automatic alignment and subsequent analysis of 3D point cloud datasets. The technology was initially created in the Department of Electronic and Electrical Engineering at University College London and then, on 1st January 2018, exclusively licensed to Correvate. It has since been enhanced by both Correvate and UCL into the Vercator® product suite www.vercator.com Vercator software provides fast, robust point cloud processing to enable automated 3D understanding of the environment. The technology can be applied to 3D point cloud datasets created using any scanning technology of any wavelength. Correvate’s first market sector is in construction – where professionals such as surveyors, architects and construction engineers create a ‘digital twin’ of the target project, yielding improvements in productivity well-recognised both by the professionals themselves and by the grant-giving teams in the UK’s Department of Business, Energy and Industrial Strategy.

Intrinsic Semiconductor Technologies focuses on developing silicon-oxide-based resistive random-access memory (RRAM) technologies. The company specializes in creating memristive devices that serve as next-generation non-volatile memory solutions. Their technology is fully air stable and compatible with complementary metal-oxide-semiconductor (CMOS) processes, allowing for integration into standard devices even at advanced process nodes. This capability enables the production of low-power, cost-effective semiconductors that can operate under higher power ratings, including elevated frequencies and temperatures. Intrinsic's offerings can be configured for various applications, such as multilevel memory, hardware acceleration for machine learning, and neuromorphic computing, positioning the company at the forefront of innovation in the semiconductor industry.

Autolus Therapeutics is a biopharmaceutical company based in London, established in 2014 by Tim Funnell and Martin Pule. The company focuses on developing next-generation programmed T-cell therapies aimed at treating cancer. Its clinical-stage pipeline includes several candidates, such as Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8.

Intract Pharma Limited is a company focused on oral drug delivery and product development, specializing in proprietary formulation technologies aimed at treating gastrointestinal and systemic immune-mediated inflammatory diseases. By leveraging advanced gastrointestinal models, Intract Pharma seeks to transform potent injectable biologic medicines into safe and convenient oral pills. This approach is designed to meet the needs of patients with chronic conditions, providing them with easier access to effective therapies while enhancing their overall treatment experience.

Apollo Therapeutics is a biopharmaceutical company based in Cambridge, United Kingdom, that collaborates with three leading UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies. The company focuses on translating groundbreaking medical research into effective therapeutics, facilitating the development of pre-clinical and clinical-stage assets. Apollo Therapeutics manages a venture capital fund that provides financial and technical support for innovative projects sourced from top British academic research, with a particular emphasis on areas such as oncology, major inflammatory disorders, and rare diseases. By leveraging its experienced team of industry scientists, Apollo aims to optimize therapeutic delivery and enhance patient treatments and outcomes, establishing a strong link between academia and the pharmaceutical industry to foster impactful medical advancements.

Appredict Ltd is a data analysis company focused on the development lifecycle of mobile applications. It utilizes advanced machine learning and optimization techniques to extract valuable insights from complex data sets. By providing app developers with a deeper understanding of their applications, Appredict aims to help them enhance their products and maximize revenue opportunities. The company's approach is rooted in award-winning research, positioning it as a leader in the field of app analytics.

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

3D Repo Ltd. is a company that specializes in developing open source version control software solutions for large-scale 3D architectural models, focusing on the construction industry. Its primary offering is an open source 3D building information modeling (BIM) version control system that enables designers, architects, engineers, and operators to collaborate in real-time through a cloud-based platform. The company provides additional services, including on-premise hosting, technical support, research and development consulting, and commercial licensing options. By delivering dynamic BIM models and metadata, 3D Repo helps clients mitigate errors and maintain project timelines and budgets. Founded in 2014 and based in London, the company aims to enhance the efficiency and effectiveness of construction projects through innovative technology solutions.

The SolveEngine is designed for solving any type of problem enabling you to do things with your business you could previously only dream about. Use the one-stop-source for state of the art optimisation algorithms and you can get immediate access to cutting edge technologies to solve even the hardest problems. Innovative algorithms are produced in academia yet rarely reach industry. The pace of change means that most planning and optimisation software is ageing and outdated. Their optimisation solutions are available “as-a-service” on demand, or on-premise, as a hybrid cloud or as a standalone solution – whatever suits your individual needs. They take the complexity out of solving optimisation problems, delivering real-world efficiencies and real-time improvements to increase your competitiveness. Companies use Satalia to solve their most challenging optimisation problems in Telecommunications, Financial services, System design and Drug discovery.

​Brainminer Ltd has developed an automated system for analysing MR brain scans. Brainminer was founded in 2015 by the Academic inventors and UCLB, the business arm of University College London, with the purpose of commercialising the exciting new machine learning algorithms that have been created for brain analysis at UCL and elsewhere. You can find out more about the company's foundation here. The company has received over £1M of funding from 2 SBRI awards in 2015 and 2016. The company’s first product, DIADEM, is CE marked and medically approved.

HeLP Digital CIC is developing digital interventions in the area of diabetes management in order to provide those whose lives are impacted by diabetes to achieve better self management of their condition. Such as, HeLP Diabetes, a web-based self-management programme and structured education for NHS patients with type 2 diabetes developed by a multidisciplinary group of academics and clinicians headed by Professor Elizabeth Murray, Director of the UCL e-Health Unit.

Bramble Energy Ltd. is a London-based company that specializes in the design, development, and manufacture of printed circuit board (PCB) fuel cells, specifically proton exchange membrane fuel cells (PEMFCs). Incorporated in 2015, it leverages the capabilities of the global PCB industry to produce high-performance, cost-effective fuel cell stacks. The company's product lineup includes modular PCBFC stacks, ranging from 20 W to 5 kW, as well as custom-designed solutions. Bramble Energy serves various sectors, including stationary, portable, and automotive applications, aiming to provide gigawatts of fuel cell hardware. By utilizing innovative manufacturing methods and materials, the company enables clients to reduce energy consumption and lower their carbon footprints.

Re:infer is a Conversational Data Intelligence platform designed to help enterprises optimize customer experience and enhance operational efficiency. The platform leverages artificial intelligence and machine learning to analyze conversational data, providing real-time, structured annotations that capture the meaning and emotion in messages. This enables organizations to automate service requests and streamline business processes effectively. With a zero-code user interface, Re:infer allows business experts and developers to create machine learning and natural language processing models swiftly and at scale. As a spinout from University College London, Re:infer is backed by notable investors, including Seedcamp and prominent figures in the AI sector.

SmartTarget specializes in developing advanced image fusion technology aimed at enhancing the diagnosis and treatment of prostate cancer. The company’s innovative software integrates diagnostic information from ultrasound, magnetic resonance imaging (MRI), and prior biopsy results, allowing clinicians to accurately identify the location, size, and shape of tumors. This technology facilitates precise targeting during prostate biopsies and minimally invasive cancer treatments. The SmartTarget device is CE-marked and designed to be compatible with various MR and ultrasound equipment, making it user-friendly and easily incorporable into existing clinical workflows. With support from the UK’s Department of Health and the Wellcome Trust, SmartTarget aims to provide an affordable solution for both public and private healthcare sectors, ultimately improving patient outcomes in prostate cancer care.

Yaqrit Limited is a clinical-stage life sciences company focused on developing innovative treatments for liver disease, particularly advanced conditions such as cirrhosis and its complications, as well as non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). With over 650 million individuals worldwide affected by chronic liver disease and associated economic costs exceeding €15.8 billion annually, Yaqrit aims to address the limited treatment options currently available, which primarily consist of antibiotics, laxatives, and liver transplants. The company combines technical expertise with clinical trial design and execution, leveraging a global network of collaborators to expedite the development of its treatment programs. By focusing on preventing, treating, and potentially reversing advanced liver disease, Yaqrit seeks to significantly improve patient outcomes and transform the lives of those suffering from these serious health conditions.

Puridify conducts research and development activities on bioprocessing technologies aimed at advancing industrial biomolecule manufacture. The company was founded by Tom Haywood, Oliver Hardick, and Iwan Roberts in March 2013 and is based in United Kingdom.

AtoCap specializes in microencapsulation technology aimed at enhancing the delivery of generic antibiotics for urinary tract infections. The company employs advanced electrohydrodynamic processing techniques to create innovative multi-layered capsules that encapsulate both antibiotics and chemotherapeutics. This method allows for effective medication administration, improving patient outcomes and minimizing recurrence rates of infections. AtoCap's team, which originated from University College London’s Encapsulation Research Group, possesses strong expertise in academia, clinical applications, and commercialization, enabling them to translate cutting-edge technologies into viable business opportunities that benefit stakeholders and investors.

Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

Abcodia Ltd. is a biotechnology company that specializes in the discovery and validation of molecular biomarkers to enhance disease diagnosis and screening, particularly for cancer. The company offers the Roca Test, which is designed for early detection of ovarian cancer, serving clients across various states in the United States as well as in the United Kingdom. Abcodia leverages a unique longitudinal serum biobank and collaborates with institutions like University College London and major diagnostic firms to facilitate comprehensive diagnostic development. Founded in 2010, Abcodia is headquartered in London, United Kingdom.

Nozzle.ai is an eCommerce and advertising optimization platform for Amazon. Nozzle.ai delivers direct-to-consumer level insights about customers on Amazon to beat the competition and grow businesses. Nozzle.ai aims to simplify the selling experience on Amazon.

The Trim Tots healthy lifestyle programme has been developed by a team of child health professionals from the Institute of Child Health together with a team of community artists, experienced in delivering educational art workshops to young children. The focus is on prevention rather than treatment of obesity. The aim of this evidence based community programme is to promote a healthy lifestyle both in pre-school children, aged between one and five, and their carers. The 24-week intervention is delivered as one two hour session per week over a 24 week period. The programme includes nutrition education, physical activity and behaviour change components with an emphasis on family involvement and learning through art and play. Trim Tots Community Interest Company aims to tackle obesity through the delivery and national roll out of Trim Tots Healthy Lifestyle Programme. Trim Tots is the only evidence based intervention programme with two-year follow up data. The overarching aim is to make Trim Tots available to all children under 5 and parent’s or carers thereof to ensure a healthy approach to early years growth and development.

ThioLogics has developed an innovative site-specific conjugation platform aimed at advancing the next generation of biologics. This technology enables the selective and stable modification of disulfide bonds or free cysteine in proteins and peptides, facilitating the creation of homogeneous products. Such modifications are particularly beneficial for producing antibody-drug conjugates (ADCs), which have been shown to possess a significantly improved therapeutic index compared to heterogeneous formulations. By enhancing the homogeneity of protein conjugates, ThioLogics' platform not only improves therapeutic efficacy but also simplifies development processes, resulting in reduced costs.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly focusing on MRI scanners. The company provides a cloud-based data analysis platform that ensures the calibration of images is traceable to standardized values. Its innovative cylindrical phantom design addresses the need for multiple sample vials during phantom preparation, allowing clinicians, medical physicists, and radiographers to obtain reproducible quantitative measurements of diseases across different patients, scanners, and clinics. This approach not only enhances the accuracy of MRI imaging but also holds the potential to reduce medical costs over time.

Therakind Limited is a pediatric healthcare company based in London, United Kingdom, founded in 2006. The company focuses on creating, developing, and improving specialty medicinal products specifically for children and other underserved patient groups. Therakind's key products include Buccolam, a treatment for prolonged acute convulsive seizures in children, and Ayendi, an intranasal pain control medication. The company targets unmet medical needs in pediatric and geriatric markets, aiming to enhance the availability of safe and effective authorized medicines. In addition to its flagship products, Therakind is engaged in developing treatments in various therapeutic areas, including cytotoxic, diabetic, sedation, antibiotic, and endocrinology. By designing more patient-friendly dosing options, Therakind seeks to improve medication adherence and broaden access to necessary treatments for its target populations.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

Endomag is a medical technology company focused on enhancing cancer care standards globally. Founded in 2007 as a spin-out from the University of Houston and University College London, the company has developed advanced magnetic sensing technology that aids in minimally invasive surgical guidance. Its key products, including the Sentimag probe, Magseed marker, and Magtrac node marker, are utilized by leading physicians and cancer centers worldwide. Endomag's mission is to help women with breast cancer avoid unnecessary surgeries and achieve better outcomes when surgery is required. Since its inception, the company has assisted over 70,000 women in accessing more precise and less invasive breast cancer care. Headquartered in Cambridge, United Kingdom, Endomag distributes its products across Europe, the Middle East, Africa, and Australasia.

CBK Sci Con are a consultancy devoted to the provision of high end scientific, technical and management advice to your business in e-science domains. CBK Sci Con was formed by one of UCL’s leading computational scientists, Professor Peter Coveney, Paul Best – an industrialist with a career in complex engineered systems and Dr Riam Kanso, a cognitive neuroscientist working in computational life and medical sciences. They have brought their combined experience of over 60 years across industry and academe, to form CBK to develop and apply e-science expertise to complex business problems.

SoftV is a new generation of gamification company, based in London focussing on Neuroscience and related medical applications. Our aim is to develop and deliver apps, games and online services to the benefit of the wider public and patient community on Mobile, Tablet, Console and PC for use at home and in a clinical context. The two company founders have over 30 years of collective experience within interactive systems and games development.

Newtec Vascular Products Ltd is developing a device which addresses Neo Intimal Hyperplasia - the blockage of vessels by scar tissue as a result of vascular graft surgery. The device has shown good efficacy in pre-clinical studies and Newtec are currently preparing for their first-in-man trials. FloGuardian™ has the potential to be used in more than 2 million procedures per year with a market potential of more than £800m.

Amalyst Limited is a developer of catalyst technology focused on applications in fuel cells and electrolysers. Based in London, the company specializes in creating electrode catalysts that serve as essential components in proton exchange membrane fuel cells and water electrolysers, facilitating energy conversion processes. Established in 2012, Amalyst aims to provide alternatives to traditional platinum-based catalysts, offering innovative solutions that can be used as drop-in replacements. Its technology enables clients to utilize high surface area catalysts made from materials such as carbon and graphite, enhancing performance while reducing reliance on precious metals.

Canbex Therapeutics, based in London, United Kingdom, focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative disorders. Founded in 2005, the company is committed to addressing the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex's lead program seeks to enhance the quality of life for patients suffering from this challenging and incurable condition, with the aim of establishing a new standard in the management of spasticity.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, specializing in contract research and contract manufacturing services focused on drug discovery. Established in 2001, the company offers a comprehensive range of services including medicinal chemistry, computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex also employs advanced technologies for hit identification and combinatorial domain hunting. The company is particularly noted for its work in developing innovative treatments for inflammatory diseases, such as DMXD-011, a small-molecule inhibitor targeting TBK1/IKKε/SIK2 for conditions like rheumatoid arthritis and lupus. Through its capabilities in biology and chemistry, Domainex aims to assist healthcare professionals in addressing complex drug discovery challenges, particularly in oncology and related fields.

Helicon Health delivers digital healthcare to improve outcomes and reduce the cost of chronic disease.

Imanova has world-leading expertise in imaging sciences and their application to the understanding of disease and translational drug development. An innovative joint venture, Imanova’s shareholders are the UK's Medical Research Council and three world-class London universities: Imperial College London, King’s College London and University College London. Imanova is a company with a depth of understanding in drug development and extensive experience using imaging to facilitate the development pipeline. Our academic expertise and extensive links with clinicians and scientists in our shareholder institutions provide unrivaled capabilities to facilitate drug development.

Nanogenics Ltd is a biotechnology company focused on developing artificial viruses to enhance gene therapy delivery. The company is creating LipTide, a synthetic peptide nanoparticle designed to act as a customizable delivery system for gene therapy. LipTide mimics natural viruses while circumventing the issues associated with traditional viral delivery methods. This innovative approach allows for targeting specific cell types and delivering various therapeutic payloads, potentially increasing delivery rates and specificity compared to conventional liposomal vectors. By addressing the critical challenge of gene therapy delivery, Nanogenics aims to advance the development of effective treatments in the biotechnology sector.

Chirp is dedicated to simplifying connectivity through the use of sound. The company has developed machine-to-machine communication software that allows devices equipped with loudspeakers or microphones to exchange data via inaudible sound waves. This innovative approach is supported by extensive research and a skilled engineering team, enabling the seamless interconnection of millions of devices in a scalable and cost-effective manner. By enhancing the end-user experience and adding value to existing hardware, Chirp positions itself as a leader in sound-based data transmission technology.

Canbex Therapeutics, based in London, United Kingdom, focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative disorders. Founded in 2005, the company is committed to addressing the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex's lead program seeks to enhance the quality of life for patients suffering from this challenging and incurable condition, with the aim of establishing a new standard in the management of spasticity.